Literature DB >> 16183657

Contribution of nuclear and extranuclear polyQ to neurological phenotypes in mouse models of Huntington's disease.

Caroline L Benn1, Christian Landles, He Li, Andrew D Strand, Ben Woodman, Kirupa Sathasivam, Shi-Hua Li, Shabnam Ghazi-Noori, Emma Hockly, Syed M N N Faruque, Jang-Ho J Cha, Paul T Sharpe, James M Olson, Xiao-Jiang Li, Gillian P Bates.   

Abstract

In postmortem Huntington's disease brains, mutant htt is present in both nuclear and cytoplasmic compartments. To dissect the impact of nuclear and extranuclear mutant htt on the initiation and progression of disease, we generated a series of transgenic mouse lines in which nuclear localization or nuclear export signal sequences have been placed N-terminal to the htt exon 1 protein carrying 144 glutamines. Our data indicate that the exon 1 mutant protein is present in the nucleus as part of an oligomeric or aggregation complex. Increasing the concentration of the mutant transprotein in the nucleus is sufficient for and dramatically accelerates the onset and progression of behavioral phenotypes. Furthermore, nuclear exon 1 mutant protein is sufficient to induce cytoplasmic neurodegeneration and transcriptional dysregulation. However, our data suggest that cytoplasmic mutant exon 1 htt, if present, contributes to disease progression.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16183657     DOI: 10.1093/hmg/ddi340

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  55 in total

1.  Disruption of the nuclear membrane by perinuclear inclusions of mutant huntingtin causes cell-cycle re-entry and striatal cell death in mouse and cell models of Huntington's disease.

Authors:  Kuan-Yu Liu; Yu-Chiau Shyu; Brett A Barbaro; Yuan-Ta Lin; Yijuang Chern; Leslie Michels Thompson; Che-Kun James Shen; J Lawrence Marsh
Journal:  Hum Mol Genet       Date:  2014-11-14       Impact factor: 6.150

2.  A critical window of CAG repeat-length correlates with phenotype severity in the R6/2 mouse model of Huntington's disease.

Authors:  Damian M Cummings; Yasaman Alaghband; Miriam A Hickey; Prasad R Joshi; S Candice Hong; Chunni Zhu; Timothy K Ando; Véronique M André; Carlos Cepeda; Joseph B Watson; Michael S Levine
Journal:  J Neurophysiol       Date:  2011-11-09       Impact factor: 2.714

Review 3.  Pathological implications of nucleic acid interactions with proteins associated with neurodegenerative diseases.

Authors:  Yraima Cordeiro; Bruno Macedo; Jerson L Silva; Mariana P B Gomes
Journal:  Biophys Rev       Date:  2014-01-09

Review 4.  Neuronal Ca(2+) dyshomeostasis in Huntington disease.

Authors:  Marta Giacomello; Juan C Oliveros; Jose R Naranjo; Ernesto Carafoli
Journal:  Prion       Date:  2013-01-01       Impact factor: 3.931

5.  Probing the Huntingtin 1-17 membrane anchor on a phospholipid bilayer by using all-atom simulations.

Authors:  Sébastien Côté; Vincent Binette; Evgeniy S Salnikov; Burkhard Bechinger; Normand Mousseau
Journal:  Biophys J       Date:  2015-03-10       Impact factor: 4.033

6.  Proteolysis of mutant huntingtin produces an exon 1 fragment that accumulates as an aggregated protein in neuronal nuclei in Huntington disease.

Authors:  Christian Landles; Kirupa Sathasivam; Andreas Weiss; Ben Woodman; Hilary Moffitt; Steve Finkbeiner; Banghua Sun; Juliette Gafni; Lisa M Ellerby; Yvon Trottier; William G Richards; Alex Osmand; Paolo Paganetti; Gillian P Bates
Journal:  J Biol Chem       Date:  2010-01-19       Impact factor: 5.157

7.  Free-Energy Landscape of the Amino-Terminal Fragment of Huntingtin in Aqueous Solution.

Authors:  Vincent Binette; Sébastien Côté; Normand Mousseau
Journal:  Biophys J       Date:  2016-03-08       Impact factor: 4.033

8.  Cytoplasmic retention of polyglutamine-expanded androgen receptor ameliorates disease via autophagy in a mouse model of spinal and bulbar muscular atrophy.

Authors:  Heather L Montie; Maria S Cho; Latia Holder; Yuhong Liu; Andrey S Tsvetkov; Steven Finkbeiner; Diane E Merry
Journal:  Hum Mol Genet       Date:  2009-03-11       Impact factor: 6.150

9.  Nucleocytoplasmic shuttling activity of ataxin-3.

Authors:  Sandra Macedo-Ribeiro; Luísa Cortes; Patrícia Maciel; Ana Luísa Carvalho
Journal:  PLoS One       Date:  2009-06-08       Impact factor: 3.240

Review 10.  Nuclear accumulation of polyglutamine disease proteins and neuropathology.

Authors:  Lauren S Havel; Shihua Li; Xiao-Jiang Li
Journal:  Mol Brain       Date:  2009-07-03       Impact factor: 4.041

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.